Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Xencor, Inc. (NASDAQ:XNCR) announced new data presentation from its preclinical bispecific antibody and IL-12-Fc cytokine programs at the AACR Annual Meeting. The data showcases the potential of CD28 and XmAb 2+1 platforms, emphasizing their engineered cytokines' enhanced therapeutic indices. Notably, Xencor plans to submit an IND for their XmAb819 bispecific antibody in 2021 and start a Phase 1 study in early 2022. The IL-12-Fc fusions showed significant anti-tumor activity in preclinical models, indicating a promising future for Xencor's innovations in cancer therapies.
Xencor, Inc. (NASDAQ: XNCR) announced it will present preclinical data on three XmAb® bispecific antibody programs and the IL-12-Fc cytokine program at the AACR Annual Meeting virtually from April 10-15, 2021. Key abstracts include:
- IL12 Fc-fusions with strong anti-tumor activity.
- PDL1-targeted bispecific antibodies enhancing T cell activation.
- Bispecific claudin-6 x CD3 antibodies targeting ovarian cancer.
- Affinity tuned XmAb® antibodies showing activity in liver cancer models.
Posters will be available for registrants starting April 10.
Xencor, Inc. (NASDAQ:XNCR) announced that its CEO, Bassil Dahiyat, Ph.D., will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on March 10, 2021, at 2:25 p.m. ET. A live webcast will be available on the company's website, with a replay accessible for 30 days afterward. Xencor focuses on developing engineered monoclonal antibodies and cytokines for treating cancer and autoimmune diseases, with 20 candidates currently in clinical development utilizing its XmAb® antibody engineering technology.
Xencor, Inc. (NASDAQ:XNCR) and UCLA Technology Development Group have partnered to develop new therapeutic antibodies using Xencor's XmAb® technology. This collaboration aims to expedite the creation of innovative biologics, addressing previously challenging biological targets. Xencor's platforms allow for the production of bispecific antibodies and engineered cytokines, with 20 clinical-stage candidates currently advancing. Notably, two Xencor-engineered antibodies have already received FDA approval for treating severe blood disorders and non-Hodgkin lymphoma.
Xencor, Inc. (NASDAQ:XNCR) reported its financial results for Q4 and full year 2020, showing revenues of $41.9 million for Q4 and $122.7 million for the year, down from $3.5 million and $156.7 million in 2019, respectively. The company reported a net loss of $13.7 million for Q4, significantly improved from a $26.9 million loss in 2019, but a full-year net loss of $69.3 million compared to a profit of $26.9 million in 2019. Xencor plans to end 2021 with $425-$475 million in cash, supporting ongoing R&D initiatives, including studies of its bispecific antibodies.
Xencor, Inc. (NASDAQ:XNCR) will release its fourth quarter and full year 2020 financial results on February 23, 2021, after market closure. A conference call and webcast for discussion of the results and corporate updates will follow at 4:30 p.m. ET. Interested parties can access the call via phone or through the company's website. Xencor is engaged in developing engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, with 20 candidates in clinical development utilizing its XmAb technology.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, announced participation in two upcoming investor conferences focused on oncology and healthcare.
- Guggenheim Healthcare Talks | 2021 Oncology Days: February 11-12, 2021, with a presentation on February 11 at 1:00 p.m. EST.
- 10th Annual SVB Leerink Global Healthcare Conference: February 22-26, 2021, with a presentation on February 24 at 3:00 p.m. EST.
Live webcasts will be available on the company's website, with replays for 30 days post-event.
Xencor (NASDAQ:XNCR) has entered a strategic research collaboration with MD Anderson Cancer Center to develop innovative CD3 bispecific antibody therapeutics aimed at cancer treatment. This partnership combines Xencor's XmAb® technology with MD Anderson's antibody research expertise. The collaboration includes preclinical development of undisclosed antibody candidates, with Xencor obtaining licensing options for potential new medicines. This initiative aims to advance antibody-based therapies that enhance immune responses against tumors, addressing an urgent need in cancer treatment.
Xencor, Inc. (NASDAQ:XNCR) has announced a research collaboration and license agreement with Janssen Biotech. This partnership focuses on developing XmAb bispecific antibodies targeting CD28 and a prostate tumor, aimed at treating prostate cancer. Xencor will receive an upfront payment of $50 million and potential future milestone payments and royalties on sales. Both companies will explore combination therapies using their respective drug candidate portfolios. The agreement is pending customary closing conditions, with expected completion by year-end.
Xencor, Inc. (NASDAQ:XNCR) reported updated data from a Phase 1 study of vibecotamab (XmAb®14045), a bispecific antibody targeting CD123 and CD3 in patients with relapsed or refractory acute myeloid leukemia (AML). Presenting at the 62nd ASH Annual Meeting, the results showed a 15% overall response rate with durable responses in some patients. The most common toxicity was mild-to-moderate cytokine release syndrome (CRS), affecting 61% of participants. Xencor's next steps include further development of vibecotamab, particularly in patient populations with minimal residual disease.